Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Jan 6, 2011 (rev. 1)


BioMérieux this week announced the appointment of James Whelan as executive vice president of commercial services.

In this newly created role, Whelan will be responsible for reinforcing BioMérieux's global service offering, which will include expanded customer lab audits, laboratory accreditation support, and comprehensive scientific training programs, BioMérieux said.

Prior to joining BioMérieux, Whelan was president of clinical diagnostics at Magellan Biosciences. From 2003 to 2007, he worked at Laboratory Corporation of America; and prior to that he worked at Fisher Scientific (now Thermo Fisher), where he held sales and management positions for 21 years.

Danish molecular diagnostics firm FluimediX said this week that Ove Öhman has joined the company's board as a non-executive director.

Öhman helped found Åmic, a Swedish diagnostic company for which he also served as chairman, CEO, and vice president of R&D for more than 10 years prior to its acquisition by Johnson & Johnson in 2008. Öhman has also held positions with Biacore, Pharmacia, and Toolex Alpha. He is currently a co-founder and CEO of Fiomi Diagnostics.

FluimediX is developing the NanoCycler point-of-care diagnostic platform for identifying SNPs for diagnosing and treating diseases.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.